VNA
ESPR icon

Valley National Advisers’s Esperion Therapeutics ESPR Stock Holding History

Valley National Advisers’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-40
Closed – – 782
2018
Q3 		$0 Buy
+40
New +$1.84K ﹤0.01% 702

Other funds holding ESPR

BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Valley National Advisers's ESPR Position: Q4 2018 in Review

Valley National Advisers sold out of Esperion Therapeutics (ESPR) in Q4 2018, closing a stake of 40 shares.

Valley National Advisers first reported a position in ESPR in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 156 funds tracked by Wall St. Rank hold ESPR as of Q4 2018.

  • Valley National Advisers reported no remaining Esperion Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Valley National Advisers sold 40 Esperion Therapeutics shares in Q4 2018.
  • Valley National Advisers first reported a position in Esperion Therapeutics in Q3 2018 and held it in 1 quarter.
  • Valley National Advisers's Esperion Therapeutics position peaked at $0 in Q3 2018.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2018.

Based on Valley National Advisers's 13F filing for Q4 2018, filed 25 Feb 2019.